Literature DB >> 24444868

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.

Joseph M Brandwein1, Eshetu G Atenafu2, Andre C Schuh3, Karen W L Yee3, Aaron D Schimmer3, Vikas Gupta3, Mark D Minden3.   

Abstract

We retrospectively evaluated the outcome of 156 adults age 17-60 with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-inspired protocol. The CR rate was 93%; 5-year overall survival (OS) and disease-free survival were 66% and 70%, respectively. Age <34 years and low presenting WBC were independent predictors of favorable OS (p<0.0001). The 5 year OS of patients age <34 and 34-60 presenting with a low WBC were 85% and 57%, respectively; the 5 year OS for those presenting with a high WBC were 57% and 30%, respectively. Cytogenetics and phenotype were not independent predictors of OS.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Chemotherapy; Leukemia; Prognostic factors

Mesh:

Substances:

Year:  2013        PMID: 24444868     DOI: 10.1016/j.leukres.2013.10.025

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

Authors:  Ghayas C Issa; Hagop M Kantarjian; C Cameron Yin; Wei Qiao; Farhad Ravandi; Deborah Thomas; Nicholas J Short; Koji Sasaki; Guillermo Garcia-Manero; Tapan M Kadia; Jorge E Cortes; Naval Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Issa Khouri; Partow Kebriaei; Richard E Champlin; Sherry Pierce; Susan M O'Brien; Elias Jabbour
Journal:  Cancer       Date:  2016-10-03       Impact factor: 6.860

2.  Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.

Authors:  Matthew D Seftel; Donna Neuberg; Mei-Jie Zhang; Hai-Lin Wang; Karen Kuhn Ballen; Julie Bergeron; Stephen Couban; César O Freytes; Mehdi Hamadani; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Taiga Nishihori; Kristjan Paulson; Wael Saber; Stephen E Sallan; Robert Soiffer; Martin S Tallman; Ann E Woolfrey; Daniel J DeAngelo; Daniel J Weisdorf
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.